TScan Therapeutics registers Phase 3 trial of TSC-101 for AML and MDS transplant patients

TScan Therapeutics had one registry update this week, a newly listed Phase 3 trial.

• TSC-101, a donor-derived engineered T-cell therapy, is being tested in a Phase 3 study called "ALLOHA-2" (NCT07702578), registered July 14, 2026 and recruiting. The trial will evaluate the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2, comparing TSC-101 plus standard of care against standard of care alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors for AML or MDS.¹ The study plans to enroll approximately 310 participants, with approximately 155 participants in each study arm¹, and its primary outcome is relapse-free survival, used to determine the efficacy of TSC-101.¹